Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim

Abstract excerpt

OBJECTIVES: Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the treatment of invasive fungal infections. Here we determined the activity of olorofim against Madurella mycetomatis, the main causative agent of eumycetoma. METHODS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Actinomycetales infections and treatment
• Share to Cancer therapeutics and mechanisms
• Share to Microbial Natural Products and Biosynthesis